Oral Anti Diabetic Agents in the Hospital
Running, not enrolling · Phase 4
Conditions studied: Diabetes Mellitus
In brief
This randomized controlled clinical trial will assess whether continuation of home oral antidiabetic agents during hospitalization can be used as a safe and effective alternative to insulin therapy in the management of diabetes in the hospital. The primary outcome of the study is to determine differences in glycemic control as measured by mean daily blood glucose concentration between oral antidiabetic medications and basal bolus therapy in hospitalized patients with type 2 diabetes (T2D).
Key facts
- Study ID
- NCT04416269
- Run by
- Emory University
- People needed
- 255
- Starts
- 2020-08-07
- Expected to finish
- 2026-03-01
- Last updated by the study team
- 2026-02-27
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Males or females, age 18-80 years admitted to a general medicine and surgery services
- Known history of T2D receiving OADs either as monotherapy or in combination therapy
- Admission BG < 250 mg/dl or randomization BG <250 mg/dl and not receiving basal insulin
- Patients receiving OADs in combination with GLP-1 receptor agonists (GLP-1RA) who have HbA1c <7.5% within the past three months
- HbA1c <10%
You may not qualify if…
- No known history of diabetes
- Laboratory evidence of diabetic ketoacidosis
- Subjects with a history of type 1 diabetes (suggested by BMI < 25 requiring insulin therapy or with a history of diabetic ketoacidosis, or ketonuria)
- Meeting any exclusion criteria based on specific contraindications to their home oral therapy
- Acute critical illness or cardiac surgery expected to require admission to a critical care unit
- Gastrointestinal obstruction, adynamic ileus, or expected to require gastrointestinal suction
- Medical or surgical patients expected to be kept NPO for >24-48 hours after admission or after completion of surgical procedure
- Impaired renal function (eGFR <30 ml/min)
- Current treatment with oral or injectable corticosteroid
- Mental condition rendering the subject unable to understand the nature and scope of the study
- Female subjects who are pregnant or breastfeeding at time of enrollment in the study
- New or recent onset (within two weeks) of coronavirus disease 2019 (COVID-19) infection at the time of admission
Where it is running
- Emory University Hospital Midtown — Atlanta, Georgia, United States
- Emory University Hospital — Atlanta, Georgia, United States
- Grady Memorial Hospital — Atlanta, Georgia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.